Media Summary: Jean-Jacques Kiladjian, MD, PhD, Saint-Louis Hospital & Paris Diderot University, Paris, France, discusses the Srdan Verstovek, MD, PhD, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, ... The MPN Hub were pleased to speak to Jean-Jacques Kiladjian, University of Paris, Paris, FR, during the 61st American Society ...

Ropeg In Polycythemia Vera Long Term Proud Pv And Conti Pv Results - Detailed Analysis & Overview

Jean-Jacques Kiladjian, MD, PhD, Saint-Louis Hospital & Paris Diderot University, Paris, France, discusses the Srdan Verstovek, MD, PhD, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, ... The MPN Hub were pleased to speak to Jean-Jacques Kiladjian, University of Paris, Paris, FR, during the 61st American Society ... Expert panelists Harry P. Erba, MD, PhD; Ruben A. Mesa, MD, FACP; and Srdan Verstovsek, MD, PhD, discuss the potential role ... During the 63rd ASH Annual Meeting and Exposition, the MPN Hub was pleased to speak to Jean-Jacques Kiladjian, Université ... From the Myeloproliferative Neoplasms Advances Day 2019 in London, UK, Jean-Jacques Kiladjian, MD, PhD, Saint-Louis ...

Jean-Jacques Kiladjian, MD, PhD, of Saint-Louis Hospital & Paris Diderot University, Paris, France, outlines the Srdan Verstovsek, MD, PhD, explains the rationale behind the During the MPN Hub Steering Committee roundtable discussion we invited Tiziano Barbui, Papa Giovanni XXIII Hospital, ... Jean-Jacques Kiladjian, MD, PhD, Saint-Louis Hospital, University of Paris, Paris, France, discusses the current and future ... In this interview, John Mascarenhas, MD, Icahn School of Medicine at Mount Sinai, New York, NY, discusses the ECLIPSE Prof Tiziano Barbui speaks to ecancer in an online interview for the virtual EHA 2020 meeting. He outlines the background, design ...

Jean-Jacques Kiladjian, MD, PhD of Saint-Louis Hospital & Paris Diderot University, Paris, France discusses the First-Line Treatments & Genetic Testing in During the First Annual Texas Virtual MPN Workshop, the MPN Hub spoke to our Steering Committee Chair, Jean-Jacques ... Alison Moliterno, MD, Johns Hopkins Medicine, Baltimore, MD, explains how JAK2 V617F mutations in hematopoietic stem cells ... In this presentation from the Treatment Dilemmas in

Photo Gallery

Ropeg in polycythemia vera: long-term PROUD-PV and CONTI-PV results
5-year follow up results of long-term use of ropeginterferon alfa-2b in polycythemia vera
PROUD-PV/CONTINUATION-PV studies: benefits of ropeg IFN alfa-2b for the treatment of PV
Updates on ropeginterferon in PV
Determining the Potential of Ropeginterferon Alfa-2b in Polycythemia Vera
Which factors may predict long-term outcomes with ropeginterferon alfa-2b for the treatment of PV?
Ropeginterferon alfa-2b for polycythemia vera: impacts and considerations
Ropeginterferon vs standard therapy for polycythemia vera
Ropeginterferon alpha-2b as an effective treatment against PV
Polycythemia Vera: PROUD-PV Trial
Ropeginterferon Alfa-2b for the treatment of low-risk patients with polycythemia vera
Current and future therapies for PV: ropeginterferon alfa-2b
Sponsored
Sponsored
View Detailed Profile
Ropeg in polycythemia vera: long-term PROUD-PV and CONTI-PV results

Ropeg in polycythemia vera: long-term PROUD-PV and CONTI-PV results

Jean-Jacques Kiladjian, MD, PhD, Saint-Louis Hospital & Paris Diderot University, Paris, France, discusses the

5-year follow up results of long-term use of ropeginterferon alfa-2b in polycythemia vera

5-year follow up results of long-term use of ropeginterferon alfa-2b in polycythemia vera

Srdan Verstovek, MD, PhD, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, ...

Sponsored
PROUD-PV/CONTINUATION-PV studies: benefits of ropeg IFN alfa-2b for the treatment of PV

PROUD-PV/CONTINUATION-PV studies: benefits of ropeg IFN alfa-2b for the treatment of PV

The MPN Hub were pleased to speak to Jean-Jacques Kiladjian, University of Paris, Paris, FR, during the 61st American Society ...

Updates on ropeginterferon in PV

Updates on ropeginterferon in PV

Jean-Jacques Kiladjian, MD, PhD, Saint-Louis Hospital & Paris Diderot University, Paris, France, discusses the

Determining the Potential of Ropeginterferon Alfa-2b in Polycythemia Vera

Determining the Potential of Ropeginterferon Alfa-2b in Polycythemia Vera

Expert panelists Harry P. Erba, MD, PhD; Ruben A. Mesa, MD, FACP; and Srdan Verstovsek, MD, PhD, discuss the potential role ...

Sponsored
Which factors may predict long-term outcomes with ropeginterferon alfa-2b for the treatment of PV?

Which factors may predict long-term outcomes with ropeginterferon alfa-2b for the treatment of PV?

During the 63rd ASH Annual Meeting and Exposition, the MPN Hub was pleased to speak to Jean-Jacques Kiladjian, Université ...

Ropeginterferon alfa-2b for polycythemia vera: impacts and considerations

Ropeginterferon alfa-2b for polycythemia vera: impacts and considerations

From the Myeloproliferative Neoplasms Advances Day 2019 in London, UK, Jean-Jacques Kiladjian, MD, PhD, Saint-Louis ...

Ropeginterferon vs standard therapy for polycythemia vera

Ropeginterferon vs standard therapy for polycythemia vera

Jean-Jacques Kiladjian, MD, PhD, of Saint-Louis Hospital & Paris Diderot University, Paris, France, outlines the

Ropeginterferon alpha-2b as an effective treatment against PV

Ropeginterferon alpha-2b as an effective treatment against PV

Polycythemia vera

Polycythemia Vera: PROUD-PV Trial

Polycythemia Vera: PROUD-PV Trial

Srdan Verstovsek, MD, PhD, explains the rationale behind the

Ropeginterferon Alfa-2b for the treatment of low-risk patients with polycythemia vera

Ropeginterferon Alfa-2b for the treatment of low-risk patients with polycythemia vera

During the MPN Hub Steering Committee roundtable discussion we invited Tiziano Barbui, Papa Giovanni XXIII Hospital, ...

Current and future therapies for PV: ropeginterferon alfa-2b

Current and future therapies for PV: ropeginterferon alfa-2b

Jean-Jacques Kiladjian, MD, PhD, Saint-Louis Hospital, University of Paris, Paris, France, discusses the current and future ...

CONTI-PV: a 2-year follow-up of interferon product AOP2014

CONTI-PV: a 2-year follow-up of interferon product AOP2014

Interesting

The ECLIPSE-PV trial: comparing two dosing regimens of ropeginterferon alfa-2b in patients with PV

The ECLIPSE-PV trial: comparing two dosing regimens of ropeginterferon alfa-2b in patients with PV

In this interview, John Mascarenhas, MD, Icahn School of Medicine at Mount Sinai, New York, NY, discusses the ECLIPSE

LOW-PV interim analysis: Ropeginterferon versus phlebotomy in low-risk polycythemia vera

LOW-PV interim analysis: Ropeginterferon versus phlebotomy in low-risk polycythemia vera

Prof Tiziano Barbui speaks to ecancer in an online interview for the virtual EHA 2020 meeting. He outlines the background, design ...

PROUD-PV and MPD-RC 112 trials of interferon alpha vs hydroxyurea for MPNs

PROUD-PV and MPD-RC 112 trials of interferon alpha vs hydroxyurea for MPNs

Jean-Jacques Kiladjian, MD, PhD of Saint-Louis Hospital & Paris Diderot University, Paris, France discusses the

Navigating Polycythemia Vera (PV) Treatment Options, Expert Insights from Dr. Gaby Hobbs

Navigating Polycythemia Vera (PV) Treatment Options, Expert Insights from Dr. Gaby Hobbs

First-Line Treatments & Genetic Testing in

What is the news about ropeginterferon?

What is the news about ropeginterferon?

During the First Annual Texas Virtual MPN Workshop, the MPN Hub spoke to our Steering Committee Chair, Jean-Jacques ...

Targeting JAK2 V617F VAF in polycythemia vera & the efficacy of ropeginterferon alfa-2b

Targeting JAK2 V617F VAF in polycythemia vera & the efficacy of ropeginterferon alfa-2b

Alison Moliterno, MD, Johns Hopkins Medicine, Baltimore, MD, explains how JAK2 V617F mutations in hematopoietic stem cells ...

Ropeginterferon, welcome to the US

Ropeginterferon, welcome to the US

In this presentation from the Treatment Dilemmas in